11 results
8-K
EX-99.1
NGNE
Neurogene Inc
22 Apr 24
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
4:44pm
Society for Gene and Cell Therapy (ASGCT) Annual Meeting. The data show that the NGN-401 gene therapy candidate has been generally well-tolerated
8-K
NGNE
Neurogene Inc
22 Apr 24
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
4:44pm
trial for Rett syndrome at the American Society for Gene and Cell Therapy Annual Meeting demonstrating that its NGN-401 gene therapy candidate has
425
NGNE
Neurogene Inc
18 Jul 23
Business combination disclosure
8:37am
(including any company limited by shares, limited liability company or joint stock company), firm, society or other enterprise, association
8-K
EX-2.1
NGNE
Neurogene Inc
18 Jul 23
Neurogene and Neoleukin Announce Definitive Merger Agreement
8:34am
any company limited by shares, limited liability company or joint stock company), firm, society or other enterprise, association, organization
8-K
EX-99.1
0u1a3 ke26sl
10 Jan 22
Regulation FD Disclosure
8:09am
8-K
EX-99.1
z7oowabpnh
4 Nov 21
Neoleukin Therapeutics Announces Third Quarter 2021 Financial Results and Corporate Update
4:09pm
8-K
EX-99.2
o610ksk
29 Sep 21
Regulation FD Disclosure
8:14am
8-K
EX-99.1
tdrnyy kmc2866
25 Mar 21
Neoleukin Therapeutics Announces Year End 2020 Financial Results
12:00am
8-K
EX-2.1
6fc 7xg6ubkhrgj2m
6 Aug 19
Entry into a Material Definitive Agreement
7:32am
8-K
EX-99.1
ull16bzbd9t3zey
7 Oct 15
Regulation FD Disclosure
12:00am
- Prev
- 1
- Next